糖尿病黃斑部水腫治療市場規模、佔有率和成長分析：按療法、給藥途徑、患者類型、最終用戶、分子類型、分銷管道和地區分類－2026-2033年產業預測

2024 年全球糖尿病黃斑部水腫治療市場價值為 59.1 億美元，預計到 2025 年將成長至 64.5 億美元，到 2033 年將成長至 129.4 億美元，在預測期（2026-2033 年）內複合年成長率為 9.1%。

糖尿病黃斑部水腫(DME) 治療市場的發展主要受全球糖尿病盛行率上升的驅動，而糖尿病盛行率上升又導致威脅視力的視網膜疾病發生率增加。人們對早期診斷和定期糖尿病眼科檢查的認知不斷提高，使得疾病檢測更加精準，並推動了對更有效治療方法的需求。眼科治療領域的創新，包括抗 VEGF 藥物和緩釋給藥系統，正在改善患者的治療效果，並鼓勵醫療服務提供者將這些先進療法納入常規診療實踐。醫療保健支出的成長、獲得專業眼科護理的便利性提高以及有利的保險報銷政策進一步促進了市場發展。由於老年人口的成長，患者群體也在擴大，老年人尤其容易受到糖尿病和視網膜疾病的影響。此外，人工智慧的進步正在簡化藥物研發流程並最佳化治療方案，為不斷發展的 DME 領域創造了新的成長機會。

全球糖尿病黃斑部水腫)治療市場按治療類型、給藥途徑、患者類型、最終用戶、分子類型、分銷管道和地區進行細分。依治療類型分類，市場分為抗 VEGF 療法、皮質類固醇療法、雷射光凝術、玻璃體切除手術和其他療法。依給藥途徑分類，市場分為玻璃體內注射和玻璃體內植入。依患者類型分類，市場分為與非增殖性糖尿病視網膜病變相關的 DME、與增殖性糖尿病視網膜病變相關的 DME 以及慢性/難治性 DME。按最終用戶分類，市場包括醫院、眼科診所、門診手術中心和專科眼科醫療中心。依分子類型分類，市場分為生物製藥、小分子藥物和聯合治療。依分銷管道分類，市場可分為醫院藥房、零售藥房和專科藥房。從地理來看，市場分析涵蓋北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

全球糖尿病黃斑部水腫治療市場的成長要素

全球糖尿病盛行率的不斷上升導致糖尿病性黃斑部水腫的高風險族群日益增多，從而對有效療法的需求持續成長。這一趨勢推動了研發投入的不斷增加，促使醫療機構將先進的治療方案納入標準化治療流程。因此，市場需求的擴張重振了市場，並凸顯了新藥創新帶來的商業性潛力。此外，關於更全面的醫保覆蓋的持續討論正在改善患者的就醫途徑，並擴大市場覆蓋範圍。同時，日益激烈的價格競爭使得不同醫療機構的治療費用更加親民，即使在預算有限的情況下也能獲得治療。

全球糖尿病黃斑部水腫治療市場的阻礙因素

新型生物製藥和基因療法的高成本導致醫療服務提供者和保險公司支出增加，進而造成保險覆蓋範圍的嚴格限制、報銷流程的延遲以及患者就醫管道受限，尤其是在預算敏感的市場。因此，醫生往往傾向於選擇更成熟、更經濟的療法，從而阻礙了創新產品的推廣應用，儘管這些產品具有明顯的臨床優勢。此外，保險覆蓋不足和高額自付費用降低了患者的就醫意願，影響了患者的用藥依從性，並降低了臨床實踐中的藥物利用率。這些因素共同限制了製造商的商機，並阻礙了整體市場成長。

全球糖尿病黃斑部水腫治療市場趨勢

受可生物分解植入和微針陣列日益普及的推動，全球糖尿病性黃斑部水腫)治療市場正顯著轉向緩釋眼科平台。這些創新給藥系統能夠長期持續釋放抗 VEGF 藥物，有效減少患者就診次數，並提高治療順從性。醫療專業人員高度重視這些技術，因為它們能夠維持穩定的治療濃度，並符合​​以價值為導向的醫療模式。因此，製造商正大力投資於聚合物科學和可擴展的生產方法，將緩釋解決方案定位為未來 DME 治療策略的核心要素，旨在長期保護視力。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球糖尿病黃斑部水腫治療市場規模：依治療類型分類

• 抗 VEGF 療法
• 皮質類固醇療法
• 雷射光凝療法
• 玻璃體切除手術
• 其他

全球糖尿病黃斑部水腫治療市場規模：依給藥途徑分類

• 玻璃體內注射
• 玻璃體內植入

全球糖尿病黃斑部水腫治療市場規模：依患者類型分類

• 與非增殖性糖尿病視網膜病變相關的糖尿病黃斑部水腫
• 糖尿病黃斑部水腫伴隨增生性糖尿病視網膜病變
• 慢性/難治性糖尿病黃斑水腫

全球糖尿病黃斑部水腫治療市場規模：依最終用戶分類

• 醫院
• 眼科診所
• 門診手術中心
• 專業眼科診所
• 其他

全球糖尿病黃斑部水腫治療市場規模：依分子類型分類

• 生物製劑
• 低分子化合物
• 聯合治療

全球糖尿病黃斑部水腫治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球糖尿病黃斑部水腫治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• AbbVie Inc.
• Alimera Sciences, Inc.
• Kodiak Sciences Inc.
• Oxurion NV
• Biogen Inc.
• Ocular Therapeutix, Inc.
• Kiora Pharmaceuticals, Inc.
• Ocuphire Pharma, Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch+Lomb Corporation
• Coherus BioSciences, Inc.
• Samsung Bioepis Co., Ltd.
• Biocon Biologics Ltd.
• Formycon AG
• Apellis Pharmaceuticals, Inc.
• Regeneron Pharmaceuticals, Inc.

結論與建議

Global Diabetic Macular Edema Treatment Market size was valued at USD 5.91 Billion in 2024 and is poised to grow from USD 6.45 Billion in 2025 to USD 12.94 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).

The market for diabetic macular edema (DME) treatments is driven by the increasing global prevalence of diabetes, leading to a higher incidence of vision-threatening retinal conditions. Enhanced awareness regarding early diagnosis and regular diabetic eye exams facilitates better detection, prompting demand for more effective treatments. Innovations in ophthalmic therapeutics, including anti-VEGF drugs and sustained-release delivery systems, are improving patient outcomes, encouraging providers to integrate these advanced treatments into routine care. Increased healthcare spending, better access to specialized eye care, and favorable reimbursement policies further strengthen market support. The aging population, particularly vulnerable to diabetes and retinal disorders, expands the patient base. Additionally, AI advancements are streamlining drug discovery and optimizing treatment modalities, creating new growth opportunities in the evolving DME landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Macular Edema Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Macular Edema Treatment Market Segments Analysis

The global diabetic macular edema treatment market is segmented based on treatment type, route of administration, patient type, end user, molecule type, distribution channel, and region. By treatment type, the market is categorized into anti-VEGF therapy, corticosteroid therapy, laser photocoagulation therapy, vitrectomy procedures, and other treatment options. Based on the route of administration, the market is segmented into intravitreal injections and intravitreal implants. Based on patient type, the market is divided into non-proliferative diabetic retinopathy-associated DME, proliferative diabetic retinopathy-associated DME, and chronic/refractory DME. By end user, the market comprises hospitals, ophthalmology clinics, ambulatory surgical centers, specialty eye care centers, and others. Based on molecule type, the market is classified into biologics, small molecules, and combination therapies. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and specialty pharmacies. Geographically, the market is analyzed across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Diabetic Macular Edema Treatment Market

The increasing prevalence of diabetes globally has resulted in a growing population at risk for diabetic macular edema, which ensures sustained demand for effective treatments. This ongoing trend drives continuous investment in research and development, prompting healthcare providers to integrate advanced treatment options into standard care protocols. Consequently, this expansion enhances the market and underscores the commercial potential of new pharmaceutical innovations. Additionally, improved discussions surrounding more comprehensive insurance coverage enhance patient access and market reach. Simultaneously, heightened pricing competition contributes to affordability in various healthcare environments, making treatments more accessible even amidst budget constraints.

Restraints in the Global Diabetic Macular Edema Treatment Market

The high costs associated with newer biologic and gene-therapy treatments lead to increased expenditures for healthcare providers and payers, resulting in strict formulary limitations, delayed reimbursement processes, and restricted patient access, particularly in budget-conscious markets. Consequently, physicians may opt for more established and affordable treatment options, hindering the adoption of innovative products despite their clear clinical benefits. Furthermore, gaps in insurance coverage and substantial out-of-pocket expenses contribute to patient reluctance, which in turn affects adherence rates and diminishes real-world utilization. These factors collectively limit manufacturers' revenue opportunities and impede the overall growth of the market.

Market Trends of the Global Diabetic Macular Edema Treatment Market

The Global Diabetic Macular Edema Treatment market is witnessing a significant shift towards sustained-release ocular platforms, driven by the increasing adoption of biodegradable implants and microneedle arrays. These innovative delivery systems allow for the sustained administration of anti-VEGF agents over extended periods, effectively reducing the frequency of patient visits and improving compliance. Healthcare providers favor these technologies for their ability to maintain stable therapeutic levels while aligning with value-based care models. Consequently, manufacturers are investing heavily in polymer science and scalable production methods, positioning sustained-release solutions as a pivotal component of future DME therapy strategies focused on long-term vision preservation.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Diabetic Macular Edema Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Anti-VEGF Therapy
• Corticosteroid Therapy
• Laser Photocoagulation Therapy
• Vitrectomy Procedures
• Others

Global Diabetic Macular Edema Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravitreal Injection
• Intravitreal Implant

Global Diabetic Macular Edema Treatment Market Size by Patient Type & CAGR (2026-2033)

• Market Overview
• Non-Proliferative Diabetic Retinopathy Associated DME
• Proliferative Diabetic Retinopathy Associated DME
• Chronic/Refractory DME

Global Diabetic Macular Edema Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ophthalmology Clinics
• Ambulatory Surgical Centers
• Specialty Eye Care Centers
• Others

Global Diabetic Macular Edema Treatment Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Biologics
• Small Molecules
• Combination Therapies

Global Diabetic Macular Edema Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Diabetic Macular Edema Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Route of Administration, Patient Type, End User, Molecule Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Patient Type, End User, Molecule Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Patient Type, End User, Molecule Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Patient Type, End User, Molecule Type, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Patient Type, End User, Molecule Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kiora Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Biologics Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formycon AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apellis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations